Business
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing
About this update from Renovorx, Inc.
[{"type":"text","content":" LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023. Register here.\n\n\nModerated by Scott Henry, Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research at ROTH Capital Partners, LLC, will conduct a fireside chat with Mr. Bagai, who will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx’s open label pivotal Phase III TIGeR- PaC study.\n\n\nROTH MKM Healthcare Opportunities Conference\nDate: October 12, 2023\nTime: 11:30 AM ET\nSpeaker: Shaun Bagai, CEO\nLocation: The Yale Club, New York City\nRegister: https://www.meetmax.com/sched/event_95633/conference_register.html\n\n\nTo schedule a one-on-one investor meeting with RenovoRx’s management team, please contact your ROTH MKM representative or KCSA Strategic Communications at [email protected].\n\n\nAbout RenovoRx, Inc.\n\n\nRenovoRx is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic (intravenous (IV) therapy). RenovoRx’s unique approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGemTM combines gemcitabine with a patented delivery system. It is currently being investigated under a US IND that is regulated by FDA 21 CFR 312 pathway. RenovoGem is currently in a Phase III clinical trial (TIGeR-PaC) for the treatment of locally advanced pancreatic cancer (LAPC).\n\n\nRenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sal...